Aderhold Neuroleptika minimieren 6.0 - BGSP

30Hennekens CH, Hennekens AR, Hollar D, Casey DE.(2006): Schizophrenia and increased risks of cardiovascular disease.Am Heart J. 2005 Dec;150(6):1115-21.Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL.(2002):Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.BMJ. 325(7372):1070.Joseph KS, Blais L, Ernst P, Suissa S.(1996): Increased morbidity and mortality related to asthma among asthmaticpatients who use major tranquillisers. BMJ. 312(7023):79-82.Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. (2006): Schizophrenia, neuroleptic medicationand mortality. In: Br J Psychiatry. 188(2), S. 122-127. http://ahrp.org/risks/antipsychotic/joukamaa2006.pdfMontout, C., Casadebaig, F., Lagnaoui, R., et al (2002). Neuroleptics and mortality in schizophrenia: prospective analysisof deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 57, 147-156.Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL.(2003) Prospective analysis of prematuremortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete,homogeneous population in rural Ireland. Psychiatry Research. 117(2):127-35.Mortensen PB, Juel K.(1990): Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand.81(4):372-7.Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB.(2007): Relative risk of cardiovascular and cancer mortalityin people with severe mental illness from the United Kingdom's General Practice Rsearch Database.Arch Gen Psychiatry. 64(2):242-9.Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.(2001): Antipsychotics and the risk of sudden cardiac death.Arch Gen Psychiatry 58(12):1161-7.Saugstad LF, Odegård O.(1979): Mortality in psychiatric hospitals in Norway 1950-1974. Acta Psychiatr Scand.59(4):431-47.Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH. (2004):Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med. 164(12):1293-7.Waddington JL, Youssef HA, Kinsella A.(1998):Mortality in schizophrenia. Antipsychotic polypharmacy and absence ofadjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 173:325-9.Walker AM, Lanza LL, Arellano F, Rothman KJ.(1997): Mortality in current and former users of clozapine. Epidemiology.8(6):671-7.86 Glassman AH, Bigger JT.(2001): Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.Am J Psychiatry.158 (11):1774-82.87 Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.(2001): Antipsychotics and the risk of sudden cardiacdeath. Arch Gen Psychiatry 58(12):1161-7.Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH. (2004):Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med. 164(12):1293-7.88 Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.(2001): Antipsychotics and the risk of sudden cardiacdeath. Arch Gen Psychiatry 58(12):1161-7.89 Palmer BA, Pankratz VS, Bostwick JM.(2005): The lifetime risk of suicide in schizophrenia: a reexamination. Arch GenPsychiatry. 62(3):247-53.90 Correll CU, Frederickson AM, Kane JM, Manu P.(2006): Metabolic syndrome and the risk of coronary heart disease in367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 67(4):575-83.Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G.(2004): Characterizing coronary heart disease risk in chronicschizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 49(11):753-60.Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S,Lieberman JA.(2005): A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study andmatched controls. Schizophr Res. 80(1):45-53.